Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on February 8, 2007

Stroke. 2007
Published online before print February 8, 2007, doi: 10.1161/01.STR.0000258076.04860.8e
A more recent version of this article appeared on March 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/3/1069    most recent
01.STR.0000258076.04860.8ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berge, E.
Right arrow Articles by Sandset, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berge, E.
Right arrow Articles by Sandset, P. M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
*Genetics Home Reference
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Cerebrovascular disease/stroke
Right arrow Coagulation
Right arrow Genetics of cardiovascular disease
Right arrow Acute Cerebral Infarction
Right arrow Embolic stroke

Submitted on June 20, 2006
Revised on September 24, 2006
Accepted on October 11, 2006

The Factor V Leiden, Prothrombin Gene 20210GA, Methylenetetrahydrofolate Reductase 677CT and Platelet Glycoprotein IIIa 1565TC Mutations in Patients With Acute Ischemic Stroke and Atrial Fibrillation

Eivind Berge MD, PhD*; Kari Bente Foss Haug MSc Pharm, PhD; Else Charlotte Sandset MD; Kaia Kristine Haugbro MSc; Meliha Turkovic; and Per Morton Sandset MD, PhD

From the Haematological Research Laboratory (E.B., E.C.S., K.K.H., M.T., P.M.S.), Department of Haematology and R&D Group (K.B.F.H.), Department of Clinical Chemistry, Ullevaal University Hospital, Oslo, Norway.

* To whom correspondence should be addressed. E-mail: eivind.berge{at}medisin.uio.no.

Background and Purpose--We wanted to investigate whether common prothrombotic mutations are more prevalent in patients with atrial fibrillation who have had a stroke than in healthy controls. We also wanted to assess whether early recurrent ischemic cerebrovascular events were more frequent among carriers of the factor V Leiden or the prothrombin gene mutations than among others.

Methods--We used a case-control design with 367 patients with acute ischemic stroke and atrial fibrillation (cases) and 482 healthy blood donors (controls). All mutations were detected with conventional polymerase-chain reaction protocols.

Results--The odds ratios for carriers of the factor V Leiden, prothrombin gene 20210GA, methylenetetrahydrofolate reductase 677CT, or platelet glycoprotein IIIa 1565TC (PlA2) mutation were 0.91, (95% CI, 0.51 to 1.59), 2.25 (95% CI, 0.61 to 8.90), 0.83 (0.61 to 1.13), and 0.79 (0.57 to 1.10), respectively. Early recurrent ischemic stroke and total recurrent ischemic cerebrovascular events were slightly more frequent among carriers of the factor V Leiden mutation than among noncarriers: odds ratio 1.45 (95% CI, 0.41 to 5.1), and 1.59 (0.61 to 4.1), respectively. None of the patients with recurrent ischemic cerebrovascular events had the prothrombin gene mutation.

Conclusion--These mutations are not important risk factors for thromboembolic stroke associated with atrial fibrillation. Carriers of the factor V Leiden mutation had a small, nonsignificantly higher risk of early recurrent ischemic cerebrovascular events.


Key words: atrial fibrillation • ischemic stroke • prothrombotic gene mutations